Institute of Tropical Medicine Antwerp
Foundation of Public Utility

The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Yardley, V. en_US
dc.contributor.author Croft, S. L. en_US
dc.contributor.author De Doncker, S. en_US
dc.contributor.author Dujardin, J. C. en_US
dc.contributor.author Koirala, S. en_US
dc.contributor.author Rijal, S. en_US
dc.contributor.author Miranda, C. en_US
dc.contributor.author Llanos-Cuentas, A. en_US
dc.contributor.author Chappuis, F. en_US
dc.date.accessioned 2007-12-06T14:34:35Z
dc.date.available 2007-12-06T14:34:35Z
dc.date.issued 2005 en_US
dc.identifier.issn 0002-9637 en_US
dc.identifier.other ITG-M3B en_US
dc.identifier.other ITG-M4A en_US
dc.identifier.other PARAS en_US
dc.identifier.other U-PROTO en_US
dc.identifier.other JIF en_US
dc.identifier.other ABSTRACT en_US
dc.identifier.other URL
dc.identifier.uri http://hdl.handle.net/10390/358
dc.description.abstract Clinical isolates of Leishmania, from visceral leishmaniasis (VL) cases in Nepal and from cutaneous leishmaniasis (CL) cases in Peru, were cultured using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to type species and strain. Promastigotes from 38 isolates, within eight passages from isolation, were used to infect mouse peritoneal macrophage cultures in vitro, and the amastigote sensitivity to miltefosine was determined. The concentration required to kill 50% of intracellular amastigotes from Nepalese VL isolates, all typed as Leishmania (L.) donovani (N = 24) from both Sbv responders and nonresponders, ranged from 8.7 to 0.04 microg/mL. In contrast, the concentration required to kill 50% intracellular amastigotes from isolates from Peru, typed as L.(V.) braziliensis (N = 8), was > 30 to 8.4 microg/mL, L.(V.) guyanensis (N = 2) > 30 to 1.9 microg/mL, L.(L.) mexicana (N = 1) > 30 microg/mL, and L. (V.) lainsoni (N = 4) was 3.4 to 1.9 microg/mL. This demonstrates a notable difference in the intrinsic sensitivity of Leishmania species to miltefosine in vitro. If this model can be correlated to therapeutic outcome, it may have implications for the interpretation of clinical trials. en_US
dc.language English en_US
dc.subject Protozoal diseases en_US
dc.subject Leishmaniasis en_US
dc.subject Drug therapy en_US
dc.subject Miltefosine en_US
dc.subject Leishmania en_US
dc.subject Drug sensitivity en_US
dc.title The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine en_US
dc.type Article en_US
dc.citation.issue 2 en_US
dc.citation.jtitle American Journal of Tropical Medicine and Hygiene en_US
dc.citation.volume 73 en_US
dc.citation.pages 272-275 en_US
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/16103588
dc.identifier.url http://www.ajtmh.org/cgi/reprint/73/2/272.pdf
dc.citation.jabbreviation Am J Trop Med Hyg en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record